The Beauty Health Company
NASDAQ:SKINHousehold & Personal Products
+$0.04 today
- Market cap
- $81.18M
- Beta
- 1.07
- P/E (TTM)
- -14.6
- EPS (TTM)
- -$0.05
Volume 0.05M
Average 0.95M
SKIN EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
The Beauty Health CompanyNASDAQ: SKIN
EBITDA · Q1 FY2026 · quarter ended Mar 2026
EBITDA turns positive
Q1 FY2026 EBITDA was $4.88M, compared with -$542K a year earlier. Trailing-twelve-month EBITDA was $44.16M. Over 3 fiscal years it compounded at -22.0% a year.
Context
- EBITDA amounted to 12.9% of revenue in FY2025, up 9.8 pp from a year earlier.
- EBITDA increased in 2 of the last 3 fiscal years.
What to watch
Whether EBITDA reaches the consensus estimate from 7 analysts of $21.77M (-43.8%) for the fiscal year ending Dec 2026, a slowdown from the +274.7% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- $4.88M-29.4% QoQ
- Last fiscal yearDec 2025
- $38.74M+274.7% YoY
- LTMMar 2026
- $44.16M+1106.3% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +1000.7% | -70.6% | -1071.3 pp |
| 1 year | +274.7% | -43.8% | -318.5 pp |
| 3-year CAGR | -22.0% | -18.2% | +3.8 pp |
| 5-year CAGR | -0.6% | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA history
USD · from the income statement
- Latest · FY2025
- 38.74M USD
- Year-over-year change
- +274.7%
| Period | Period end | EBITDA | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 38.74M | +274.7% |
| FY2024 | 2024-12-31 | 10.34M | +119.3% |
| FY2023 | 2023-12-31 | (53.57M) | -165.6% |
| FY2022 | 2022-12-31 | 81.6M | +123.3% |
| FY2021 | 2021-12-31 | (350.93M) | — |
EBITDA vs competitors
How SKIN compares with its peers on the latest reported figures
- Peers report in different currencies, so EBITDA is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +1106.3% is the highest of 7, against a peer median of -4.1%.
- EBITDA amounts to 14.9% of revenue for SKIN, versus a peer median of 7.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| FY2025 | CN¥86.61M CNY | +25.5% | — | 4.7% | |
| LTM Apr 2026 | $49.42M USD | -9.6% | — | 10.2% | |
| LTM Mar 2026 | $44.16M USD | +1106.3% | -22.0% | 14.9% | |
| LTM Mar 2026 | $20.68M USD | +1.4% | +25.9% | 10.2% | |
| LTM Mar 2026 | $10.86M USD | -15.9% | +21.3% | 12.0% | |
SLSNSolesence, Inc. Common Stock | LTM Mar 2026 | $3.02M USD | -42.0% | — | 5.0% |
| LTM Mar 2026 | -$6.68M USD | +61.3% | — | 3.9% | |
| Peer median (excluding SKIN) | — | -4.1% | +23.6% | 7.6% | |
Competitors are the stored peer set for SKIN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 260.09M | 365.88M | 397.99M | 334.29M | 300.79M |
| Cost of Revenue | 81.55M | 117.1M | 242.88M | 152M | 104.43M |
| Gross Profit | 178.54M | 248.78M | 155.11M | 182.3M | 196.36M |
| Gross Margin | 68.6% | 68.0% | 39.0% | 54.5% | 65.3% |
| Research & Development | 8.2M | 8.44M | 10.1M | 6.3M | 5.63M |
| Selling, General & Admin | 210.27M | 266.18M | 275.93M | 243.77M | 211.54M |
| Operating Expenses | 218.47M | 274.62M | 286.03M | 250.07M | 217.17M |
| Depreciation & Amortization | 17.93M | 22.87M | 34.68M | 29.48M | 25.35M |
| EBITDA | (350.93M) | 81.6M | (53.57M) | 10.34M | 38.74M |
| EBITDA Margin | -134.9% | 22.3% | -13.5% | 3.1% | 12.9% |
| Operating Income | (39.93M) | (25.84M) | (130.92M) | (67.77M) | (20.8M) |
| Operating Margin | -15.4% | -7.1% | -32.9% | -20.3% | -6.9% |
| Interest Income | 39K | 9.18M | 23.17M | 16.64M | 8.95M |
| Interest Expense | 11.78M | 13.39M | 13.65M | 10.41M | 19.33M |
| Other Income / Expenses | (340.71M) | 71.18M | 29.03M | 38.22M | 14.87M |
| Income Before Tax | (380.64M) | 45.34M | (101.89M) | (29.55M) | (5.94M) |
| Pre-Tax Margin | -146.4% | 12.4% | -25.6% | -8.8% | -2.0% |
| Income Tax Expense | (1.88M) | 1.12M | (1.77M) | (452K) | 3.58M |
| Net Income | (378.76M) | 44.22M | (100.12M) | (29.1M) | (9.52M) |
| Net Margin | -145.6% | 12.1% | -25.2% | -8.7% | -3.2% |
| EPS (Basic) | (3.67) | 0.30 | (0.76) | (0.23) | (0.08) |
| EPS (Diluted) | (3.67) | (0.23) | (0.76) | (0.36) | (0.16) |
| Weighted Avg Shares | 102.11M | 147.55M | 131.68M | 123.83M | 126.38M |
| Weighted Avg Shares (Diluted) | 102.11M | 148.51M | 131.68M | 142.49M | 135.8M |
The Beauty Health Company
NASDAQ:SKIN
Intrinsic Alpha fair value
Locked
Current Price
$12.46
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.